Evidence map›Paper›PMID 40109812›Full record

ArticleCureus2025

Ethambutol-Induced Optic Neuropathy: A Retrospective Study of Incidences and Risk Factors.

Priti Singh, Samendra Karkhur, Vidhya Verma

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Priti SinghOphthalmology, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.
Samendra KarkhurOphthalmology, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.
Vidhya VermaOphthalmology, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe present study aims to determine the incidences of ethambutol-induced optic neuropathy (EON) and its associated risk factors in Central Indian tertiary care centers. MATERIALS AND

methodsA single-centered retrospective observational study was conducted. Data was collected from the Directly Observed Therapy Short-course (DOTS) centre after the revised National Tuberculosis Control Program (RNTCP) 2016 guidelines were implemented. The collected data included demographic data, history of underlying diseases, such as diabetes mellitus, hypertension, HIV infection, and history of smoking. The site of tuberculosis infection, daily dose, the duration of ethambutol (EMB) treatment, onset, and type of ocular symptoms were recorded. We performed regression analyses to investigate the univariate and multivariable associations with different variables.

resultsOf the 1676 patients who received ethambutol for TB treatment, 987 had an ophthalmological symptom unrelated to EON, and 13 developed EON (incidence =0.28%). Demographic and clinical variables considered were age, gender, race/ethnicity, body mass index (BMI), and diabetes mellitus status. Examples of current infection information were chronic HIV and other comorbidities uniquely associated with renal function site/type treatment specific dose/duration ethambutol. Longer treatment duration significantly correlates with greater thickness of the left temporal retinal nerve fibre layer (RNFL) and thicker average RNFL. Increased peripapillary retinal nerve fibre layer (pRNFL) thickness on the left nasal RNFL scan was significantly correlated with ethambutol tablets (or count) (p=0.027).

conclusionThe findings indicate that ethambutol toxicity is indeed dose and duration-dependent, evidenced by the relationship between prolonged treatment and increased RNFL thickness, suggesting heightened risk of visual impairment. Moreover, adverse effects were observed at even lower doses (12.3 mg/kg), reinforcing that no dose of ethambutol is entirely safe.

Indexed as

ethambutolethambutol-induced optic neuropathy (eon)revised national tuberculosis control programme (rntcp)rnfl thicknesstuberculosis

Identifiers

PMID40109812
PMCPMC11921821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.